The PMatX Yavne incubator will serve Israeli startups and focus on next-generation electronics and advanced materials.
The number of layoffs at Neot Hovav has been reduced from 175 to 110 but there is still no agreement at the Kfar Saba plant.
US companies Church & Dwight Co. and Cooper Cos. are both interested in Teva's women's health portfolio, "Bloomberg" reports.
Teva has raised the price of Copaxone 10-fold since 1996, two US Congressmen claim.
Teva has announced the launch of generic Axiron (testosterone) topical solution. Axiron has annual sales of $247 million in the US.
The financing is for a Phase III trial for the Israeli company’s lead product, Glatiramer Acetate (Copaxone) Depot, for treating multiple sclerosis.
The National Insurance Institute pays investors if the treatment is successful.
The Israeli company has developed algorithm-rich solutions for the detection and elimination of prescription errors.
The investing company is ERA Brazil Israel, owned by Eric Ben-Mayor and partners.
Foreign media reports say the investment funds are interested in buying Teva's oncology and pain treatment divisions.
The dermatology company's unique wrapping method makes it possible to combine two anti-acne drugs.
Biotech and medical devices investor Mori Arkin: The global generics market is in a terrible state, but it wasn't unexpected.
Controlling shareholder Mori Arkin told "Globes" that he hopes the Israeli diagnostics company's IPO will be at a company value of $200-300 million.
Israel is putting too many eggs in the startup basket, warns Avi Tiomkin.
CSO Dr. Oron Yacoby-Zeevi tells about the day Neuroderm almost closed down, and how Israeli venture capital funds missed the opportunity to invest.
Pharmaceutical rivals will to try to exploit Teva's weakness and buy activities from it that are profitable, writes Omri Cohen.